LEGEND BIOTECH CORP

Legend Biotech climbs 1.45% as investors eye its cell‑therapy pipeline and value‑oriented price, amid mixed biotech and banking market moves.

Legend Biotech (LEGN) dips below its 200‑day SMA, yet its oncology‑focused cell‑therapy pipeline and strong cash position hint at upside—watch for 6‑12‑month milestones.

Legend Biotech (LEGN) climbs 0.92% on Jan 21, 2026, trading at $18.65. Discover why the cell‑therapy firm’s shares rise and what investors expect next.